CDKN2A and head and neck squamous cell carcinoma: Phase 2 and 3 trials are underway investigating palbociclib in biomarker selected patients with R/M HNSCC since the largest reduction in risk of death with palbociclib in the PALATINUS trial occurring in the subset with CDKN2A mutations [87].